[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-total-occlusion-of-coronary-artery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-total-occlusion-of-coronary-artery":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,39,66,91,117,144,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100336958","evaluation-of-effectiveness-and-safety-of-antegrade-and-retrograde-approach-of-percutaneous-coronary-intervention-for-chronic-total-occlusions-100336958",false,"NCT03667196","Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions","Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions; Systemic Chronic Total Occlusion Revascularization Korea Research-Chronic Total Occlusion (STRIKE-CTO) Study","STRIKE-CTO","Inclusion Criteria:\n\n* Patients aged\\>=19\n* Patients who have a CTO lesion in at least one or more epicardial coronary artery 2.5 mm in blood vessel diameter\n* Patients who have symptoms of angina or objectively proven myocardial ischemia (asymptomatic myocardial ischemia, stable or unstable angina, non - -ST-segment elevation myocardial infarction)\n* Patients who voluntarily agreed to the protocol and the clinical follow-up plan (or let their representative do this), and signed the informed consent form approved by the IRB of each study institute\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating or have childbearing potential Patients in whom contrast medium and heparin are contraindicated or who are hypersensitive to them\n* Patients in whom aspirin, clopidogrel, ticagrelor and prasugrel, cilostazol are contraindicated\n* Patients scheduled to undergo a surgery, etc. that requires discontinuance of an antiplatelet drug within 12 months after participation in the study\n* Acute ST elevation myocardial infarction at the time of hospitalization\n* Terminally ill patients with their life expectancy \\\u003C one year\n* Patients who have serious diseases other than cardiac diseases that may affect limitation of residual life time or observation of the protocol (e.g. oxygen-independent chronic obstructive pulmonary disease, persisting hepatitis or serious hepatic insufficiency, severe renal disease, etc. Be left up to the discretion of the investigator.)","ALL","19 Years",{"count":20,"type":21},4000,"ESTIMATED","OBSERVATIONAL","Objective of this study is to 1) analyze the clinical, anatomical and periprocedural differences of patients who underwent a procedure related to coronary CTO through the antergrade approach and retrograde approach; 2) analyze the success rate of the procedures and the incidence and patterns of complications; 3) compare and analyze long-term performances after the successful procedure; and 4) identify the independent factors that require a retrograde approach and the prognostic factor regarding long-term performances after use of each approach.",[25],"Chronic Total Occlusion of Coronary Artery","RECRUITING","2026-06-23",{"date":29,"type":30},"2026-06-25","ACTUAL",{"date":32,"type":30},"2018-01-11",{"date":34,"type":21},"2032-12-31",{"name":36,"class":37},"Seung-Whan Lee, M.D., Ph.D.","OTHER",32,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100328992","ischemia-cto-trial---revascularisation-or-optimal-medical-therapy-of-cto-100328992","NCT03563417","ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO","International Randomized Trial on the Effect of Revascularization or Optimal Medical Therapy of Chronic Total Coronary Occlusions With Myocardial Ischemia - ISCHEMIA-CTO Trial","ISCHEMIA-CTO","Inclusion Criteria:\n\n* CTO in native coronary artery\n* Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.\n* Age ≥18 yrs.\n* Able to provide written informed consent and willing to comply with the specified follow-up contacts.\n* Target artery ≥ 2.5 mm\n\nPrior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:\n\nCohort A: Asymptomatic (CCS \\\u003C 2 and SAQ QoL \\> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO\n\nCohort B: Symptomatic patients (CCS class ≥ 2 and\u002For SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO assess by nuclear imaging.\n\nCohort C: Screening population not eligible for randomization in cohort A or B\n\nExclusion Criteria:\n\n* NSTEMI or STEMI within 1 month\n* Coronary anatomy not suitable for CTO-procedure\n* Coronary disease involving the left main\u002Fthree vessel disease with indication for CABG following heart team conference.\n* Life expectancy \\\u003C 2 years\n* Severe chronic pulmonary disease (FEV1 \\\u003C 30 % of predicted value)\n* Contraindication to dual anti-platelet therapy\n* Pregnancy\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.\n* Severe valvular heart disease","18 Years",{"count":49,"type":21},1560,"INTERVENTIONAL",[52],"NA","Study design\n\nProspective randomized open labeled multicenter study\n\nHypotheses\n\n1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI (Percutaneous Coronary Intervention) with latest generation of drug eluting stents is superior to optimal medical therapy in terms of relative reduction in MACCE (Major Adverse Cardiovascular and Cerebrovascular events).\n2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy (OMT) in terms of improved life quality measured as an increase of SAQ (Self Assessment Questionnaire) score of 8 points after 6 months.\n\nInclusion Criteria\n\n* CTO in native coronary artery\n* Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.\n* Age ≥18 yrs.\n* Able to provide written Informed consent and willing to comply with the specified follow-up contacts\n* Target artery ≥ 2.5 mm\n\nPrior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:\n\nCohort A: Asymptomatic (CCS \\\u003C 2 and SAQ QoL \\> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO\n\nCohort B: Symptomatic patients (CCS class ≥ 2 and\u002For SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO\n\nCohort C: patients enrolled but not randomized in cohort A or B\n\nExclusion criteria (for both cohort A and B)\n\n* NSTEMI or STEMI within 1 month\n* Coronary anatomy not suitable for CTO-procedure\n* Coronary artery disease involving the left main\u002Fthree-vessel disease with indication for CABG following heart team conference\n* Life expectancy \\\u003C 2 years\n* Severe chronic pulmonary disease (FEV1 \\\u003C 30 % of predicted value)\n* Contraindication to dual anti-platelet therapy\n* Pregnancy\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.\n* Severe valvular heart disease\n\nPrimary endpoint\n\nCohort A: Composite endpoint of MACCE (all-cause mortality, stroke, any myocardial infarction, clinically driven revascularization\\*), hospitalization for heart failure or incidence of malignant arrhythmias.\n\n\\*CCS class ≥ 2 and\u002For QoL score \\\u003C 60. Same criteria used as for allocation to Cohort B\n\nCohort B: SAQ Quality of Life Assessment after 6 months.\n\nNumber of patients\n\n1,560 (1200 in cohort A\u002F360 in cohort B\n\nFollow up time\n\nCohort A: 5 years Cohort B: 6 months",[55,25],"Ischemic Heart Disease","2025-12-29",{"date":58,"type":30},"2026-01-02",{"date":60,"type":30},"2018-11-06",{"date":62,"type":21},"2032-11-01",{"name":64,"class":37},"Aarhus University Hospital Skejby",27,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":50,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100530989","vasostar-vibrational-guidewire-system-to-facilitate-crossing-coronary-artery-chronic-total-occlusions-100530989","NCT06193954","VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions","Evaluation of a Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions in Patients With Chronic Angina Refractory to Maximally Tolerated Guideline Directed Medical Therapy","VST100","Inclusion Criteria:\n\n* Male or female, over 18 years of age, presenting with at least one ischemia inducing lesion in a native coronary artery that is refractory to standard guidewire crossing. Chronic total occlusion (CTO) is defined as 100% coronary blockage for over a 3-month duration documented either by prior catheterization or by clinical evaluation\n* Suitable candidate for non-emergent, coronary angioplasty\n* Documented de-novo or restenotic coronary chronic total occlusion defined as a lesion with TIMI 0 flow for at least 90 days refractory to conventional guidewire crossing\n* Left ventricle ejection fraction \\> 20% within the last 12 months.\n* For antegrade chronic total occlusion procedures, activated clotting time (ACT) should be \\> 300 sec\n* Chronic total occlusion in a non-tortuous arterial segment\n* Voluntarily sign a Patient Informed Consent Form specific to the study.\n* Physically and mentally willing to comply with all study requirements.\n\nExclusion Criteria:\n\n* Successful target lesion crossing with a conventional wire system prior to enrollment\n* Prisoners.\n* Pregnancy\n* Patient has an active implantable.\n* Extensive dissection created by refractory guidewire\n* Severe ongoing congestive heart failure (New York Heart Association Class IV symptoms)\n* Active infection\n* Uncontrolled Hypertension (Systolic blood pressure \\> 180 mm) at the time of the procedure\n* History of severe reaction to contrast media\n* Recent myocardial infarction (within 2 weeks)\n* In-stent target lesion\n* Severe cerebrovascular disease including history of prior stroke or transient ischemic attack within 1 month at the time of the procedure\n* Saphenous vein graft (SVG) chronic total occlusion or an in-stent chronic total occlusion\n* Short life expectancy due to other illnesses such as cancer or pulmonary, hepatic or renal disease\n* Participation in another investigational protocol at the time of the procedure",{"count":75,"type":21},10,[52],"The goal of this project is to provide an improvement in wire performance to expedite crossing difficult lesions in the coronary vasculature.",[25,79],"Chronic Angina","2025-09-15",{"date":82,"type":30},"2025-09-16",{"date":84,"type":30},"2024-06-10",{"date":86,"type":21},"2026-12-31",{"name":88,"class":89},"VasoStar, LLC","INDUSTRY",2,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100547944","calcification-on-ctca-of-a-cto-and-pci-outcomes-100547944","NCT06414551","Calcification on CTCA of a CTO and PCI Outcomes","Characteristics of Calcification in a Chronic Total Occlusion on Computed Tomography Coronary Angiogram and Percutaneous Coronary Intervention Outcomes- a Single Centre Observational Study","Inclusion Criteria:\n\n* Patients meeting all the below criteria will be included\n\n  * ≥18 years\n  * Previous CTO PCI attempt in the last 5 years\n  * Undergone CTCA either pre or post CTO PCI\n  * Adequate CTCA images for analysis\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria will be excluded\n\n  * \\\u003C18 years of age\n  * Did not undergo CTCA\n  * Inadequate\u002Fdegraded CTCA images",{"count":99,"type":21},100,"A chronic total occlusion (CTO) is present in 15-20% of patients who are referred for invasive coronary angiography. CTO Percutaneous Coronary Intervention (PCI) procedure success rates have increased over the years and can be as high as 90% when performed by high-volume CTO operators.Procedurally, excess calcification in the CTO anatomy is one factor which makes it difficult to complete the procedure or obtain ideal stent expansion. Excess calcification is best identified by Computed Tomography Coronary Angiography (CTCA) rather than invasive angiography.\n\nThe investigators plan to retrospectively evaluate CTCA in patients who underwent CTO PCI and correlate calcification characteristics with CTO PCI outcomes and tools utilised for calcium modification.",[25,102,103],"Calcification","Computed Tomography Angiography",[105,106],"CTCA","CTO","2024-08-28",{"date":109,"type":30},"2024-08-30",{"date":111,"type":30},"2024-07-19",{"date":113,"type":21},"2025-07-01",{"name":115,"class":37},"Sandwell & West Birmingham Hospitals NHS Trust",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":50,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":116},"100343839","revascularization-versus-optimal-medical-therapy-of-chronic-total-coronary-occlusions-on-left-ventricular-ischemia-reduction-100343839","NCT03756870","Revascularization Versus Optimal Medical Therapy of Chronic Total Coronary Occlusions on Left Ventricular Ischemia Reduction","REvascularization Versus Optimal Medical Therapy on Left Ventricular ISchemia Reduction: Exploring the Associations Between Ischemia, Functional Outcome and Collaterals in the Treatment of Chronic Total Occlusion Patients","REVISE-CTO","Inclusion Criteria:\n\n1. A chronic total occlusion is present and target lesion. A CTO is required to meet the following characteristics:\n\n   * A 100% luminal narrowing of the coronary artery without antegrade flow, i.e. Thrombolysis in Myocardial Infarction flow grade 0 or 1;\n   * Older than 3 months, established with previous PCI or with angiographic characteristics;\n   * Amenable to percutaneous revascularization.\n2. Patient has a clinical indication to perform CTO PCI.\n3. A SPECT is performed at baseline to assess ischemia and a cardiac magnetic resonance imaging (CMR) scan to assess viability, as part of routine patient care. Patients are deemed eligible for the randomized trial when they meet the ischemic threshold in the CTO territory.\n\n   The ischemic threshold is defined as:\n   * \\>12.5% of ischemia;\n   * With \\\u003C50% transmural extent of infarction.\n4. Subject agrees to undergo follow-up SPECT-CT at 6 months after initial inclusion\n5. Subject is able to verbally confirm understanding and he\u002Fshe provides written informed consent prior to any Clinical Investigation related procedure, as approved by the appropriate Ethics Committee.\n\nExclusion Criteria:\n\n* Subject is younger than 18 years of age;\n* Persistent or permanent atrial fibrillation;\n* Presence of a non-MRI compatible cardiac device, i.e. pacemaker or implantable cardioverter defibrillator;\n* Body weight \\> 250 kg;\n* Unable to exert, i.e. due to physical disability;\n* Any contraindication for SPECT or CMR, i.e. cerebrovascular clips, claustrophobia;\n* Known renal insufficiency (estimated Glomerular Filtration Rate \\[eGFR\\] \\\u003C60 mL\u002Fmin\u002F1.73m2 or serum creatinine level of \\>2.5 mg\u002FdL or subject on dialysis);\n* Hypersensitivity or allergy to contrast with inability to properly pre-hydrate;\n* Presence of a comorbid condition with a life expectancy of less than one year;\n* Participation in another trial;\n* Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.",{"count":126,"type":21},82,[52],"Rationale: Randomized trials could not yet establish favourable outcomes of CTO PCI on hard endpoints such as ejection fraction or mortality, when compared to optimal medical therapy. However, patients after CTO PCI appeared to be more frequently free of angina complaints, but the aetiology behind this is not fully understood. The investigators hypothesize that PCI of the CTO in patients preselected with an ischemic threshold (\\>12.5%) on cardiac imaging leads to a reduction of the ischemic burden and therefore an increased benefit on functional outcomes.\n\nObjective: Primary objective is to determine whether PCI of the CTO will yield a higher reduction of ischemia assessed by exercise myocardial perfusion SPECT-CT from baseline to 6-month follow-up compared to a control group. Secondary objectives are 1) to evaluate the effect of PCI of the CTO on improvement in functional status, infarct size and left ventricular function from baseline to follow-up compared to the control group; 2) to study the association between ischemia reduction and functional outcome and left ventricular function; 3) to assess the influence of the collateral flow index on the ischemic burden (reduction), functional status, infarct size and left ventricular (contractile) function (hibernation).\n\nStudy design: open multicentre randomized trial\n\nStudy population: 82 patients eligible for CTO PCI\n\nIntervention: CTO PCI\n\nPrimary endpoint: ischemic burden assessed with exercise myocardial perfusion SPECT-CT from baseline to 6 months follow-up.",[25],[131,132,133,134],"Chronic total coronary occlusion","Percutaneous coronary intervention","Optimal medical therapy","Myocardial ischemia","2023-07-19",{"date":137,"type":30},"2023-07-20",{"date":139,"type":30},"2019-07-01",{"date":141,"type":21},"2030-01-01",{"name":143,"class":37},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":50,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":116},"100435008","to-evaluate-whether-ivus-guided-drug-eluting-stent-des-implantation-leads-to-better-clinical-outcomes-compared-to-conventional-angiography-in-the-treatment-of-chronic-complete-occlusion-cto-disease-100435008","NCT04944615","To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.","IVUS-CTO: Comparison of the Effect of Intravascular Ultrasound-guided Versus Angiographic-guided Drug-eluting Stent Implantation on Long-term Clinical Outcomes in Patients With Chronic Complete Occlusion of Coronary Artery Disease: a Prospective, Multicenter, Randomized Controlled Clinical Study","CRUISE-CTO","Clinical inclusion criteria:\n\n1. At least 18 years old\n2. Subjects will understand the test requirements, treatment and surgery, and can provide written informed consent\n3. Subjects with clinical symptoms of ischemic heart disease or evidence of myocardial ischemia associated with CTO target vessels and scheduled to undergo Percutaneous coronary intervention (PCI)\n4. Subjects will receive percutaneous coronary intervention\n5. Subjects are willing to accept all treatment and follow-up evaluations required by the protocol\n\nInclusion criteria for angiography:\n\n1. Primary coronary artery CTO lesion with visible collateral circulation\n2. Estimation of the time to complete occlusion (TIMI grade 0) ≥3 months based on clinical history and\u002For comparison with historical angiography or ECG\n3. It is suitable for target lesions of 2.25-4.0mm stent implantation\n4. The length of CTO lesion should be greater than 20mm\n\nClinical exclusion criteria:\n\n1. Pregnant and lactating women\n2. Severe coronary artery disease, not suitable for PCI\n3. Patients with acute myocardial infarction less than 7 days\n4. Long-term contraindications to DAPT (at least 1 year)\n5. Known renal insufficiency.20 mL\u002Fmin \u002F 1.73 ㎡)\n6. Left ventricular ejection fraction \\<35% or cardiogenic shock\n7. The ICD implanted\u002FCRT\n8. Severe bleeding or stroke within 6 months\n9. Have a history of allergy to iodine contrast agents or any known allergy to clopidogrel, ticagrelor, aspirin, or heparin\n10. Subjects have been diagnosed or suspected of liver disease, including laboratory evidence of hepatitis\n11. Valvular heart disease significantly affecting hemodynamics, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease\n12. Diseases that researchers believe may seriously harm patients, such as cancer and mental illness;Or the patient's life expectancy is less than one year and the follow-up cannot be completed;Or other conditions that researchers think might have confounded the results\n13. Participate in any other ongoing trial or intend to participate in another clinical trial of a drug or device within 12 months after baseline surgery\n\nAngiographic exclusion criteria:\n\n1. The target lesion is located in the left main artery\n2. No visible collateral circulation in CTO lesions\n3. Target lesion is venous or arterial bypass graft\n4. The target vessel occlusion time (TIMI grade 0) \\\u003C 3 months can be determined",{"count":153,"type":21},1448,[52],"This study aims to evaluate the treatment of Chronic total occlusion (CTO) disease. Whether Intravascular Ultrasonography (IVUS) guiding the implantation of drug-eluting stents (DES) will provide better long-term clinical outcomes compared with conventional angiography",[25],[158],"TIMI flow = grade 0 coronary artery disease with a duration greater than 3 months.","2023-03-27",{"date":161,"type":30},"2023-03-29",{"date":163,"type":30},"2022-10-21",{"date":165,"type":21},"2031-10",{"name":167,"class":89},"CCRF Inc., Beijing, China",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":116},"100200739","japanese-cto-pci-expert-registry-100200739","NCT01889459","Japanese CTO PCI Expert Registry","Patient Registry of Percutaneous Coronary Intervention (PCI) for Chronic Total Occlusion (CTO) by Japanese Experts","Inclusion Criteria:\n\nPatients eligible for PCI\n\nPatients who underwent PCI for CTO lesions that contain the following:\n\n1. Thrombolysis in myocardial infarction trial (TIMI) 0\n2. The occlusive period more than 3 months or unknown\n3. The main coronary arteries (segment 1-3, 5-8, 11, 13), branches that have large perfusion area (segment 4PL, 9\u002F10, 12) and graft\n\nExclusion Criteria:\n\nPatients ineligible for PCI judged in clinical practice","20 Years",{"count":177,"type":21},19000,"The purpose of this study is to establish a consensus of treatment strategy of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) through patient registry of PCI for CTO performed by Japanese certified operators.",[25],"2013-07-01",{"date":182,"type":21},"2013-07-02",{"date":184,"type":4},"2013-07",{"date":186,"type":21},"2027-12",{"name":188,"class":37},"Kurashiki Central Hospital"]